Diasorin SpA (WBO:DIAS) Stock Based Compensation: €0 Mil (TTM As of Dec. 2025)


WBO:DIAS Diasorin SpA WBO:DIAS
74 GF Score
Price €69.68
GF Value €90.06
Valuation Modestly Undervalued
! 6 Warning Signs
View Full Analysis

What is Diasorin SpA Stock Based Compensation?

Diasorin SpA WBO:DIAS +2.47% 74 Stock Based Compensation is €0 Mil as of Dec. 2025. GuruFocus rates WBO:DIAS with a GF Score™ of 74/100 and a GF Value™ of €90.06 (Modestly Undervalued). The stock has 6 warning signs investors should review.

Diasorin SpA's Stock Based Compensation for the three months ended in Dec. 2025 was €0 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Dec. 2025 was €0 Mil.

Diasorin SpA Stock Based Compensation Related Terms

Diasorin SpA Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for Diasorin SpA's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Diasorin SpA Stock Based Compensation Chart

Diasorin SpA Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Stock Based Compensation
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.43 9.54 10.04 11.04 11.11

Diasorin SpA Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
WBO:DIAS
74GF Score
Diasorin SpA WBO:DIAS
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Diasorin SpA Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €0 Mil.

What does a Stock Based Compensation of €0 Mil mean?
Diasorin SpA (WBO:DIAS) has a Stock Based Compensation of €0 Mil as of Dec. 2025. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Diasorin SpA and its competitors.
Is Diasorin SpA's Stock Based Compensation too high?
Diasorin SpA's current Stock Based Compensation is €0 Mil. Overall, Diasorin SpA has a GF Score™ of 74/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Diasorin SpA's Stock Based Compensation compare to TMO and DHR?
Diasorin SpA's Stock Based Compensation of €0 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Medical Diagnostics & Research company?
A good Stock Based Compensation depends on the Medical Diagnostics & Research industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Diasorin SpA and its competitors. Diasorin SpA's current Stock Based Compensation is €0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Diasorin SpA stock overvalued right now?
Based on GuruFocus' analysis, Diasorin SpA (WBO:DIAS) is currently considered Modestly Undervalued. The stock's GF Value™ is €90.06, compared to a current price of €69.68 — trading 22.6% below its estimated fair value. The current Stock Based Compensation is €0 Mil. Diasorin SpA's overall GF Score™ is 74/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For Diasorin SpA (WBO:DIAS), the current Stock Based Compensation is €0 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Diasorin SpA (WBO:DIAS) Overvalued in 2026?

Based on GuruFocus' analysis, Diasorin SpA stock appears to be undervalued. The current stock price of €69.68 is trading 22.6% below its estimated GF Value™ of €90.06. GuruFocus considers Diasorin SpA to be Modestly Undervalued.

Key valuation signals for WBO:DIAS:

  • Stock Based Compensation: €0 Mil
  • GF Value™: €90.06 vs. price of €69.68 (22.6% below fair value)
  • GF Score™: 74/100 with 6 warning signs

No single metric tells the full story. See the WBO:DIAS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Diasorin SpA Business Description

Address Via Crescentino Snc, Saluggia, Vercelli, ITA, 13040
Diasorin develops and manufactures a broad portfolio of in vitro diagnostics for detecting pathogens and sample contamination from the human body, as well as for use in industrial settings, such as food and water contamination testing. The company operates three segments: immunodiagnostics (69% of sales), molecular diagnostics (16%), and licensed technologies (14%). Diasorin was an important manufacturer of covid tests, which boosted its profits during the pandemic, but this segment's importance has decreased over the years, and in 2025, it accounted for only 1% of total sales.
74GF Score

Get the complete analysis for WBO:DIAS

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€69.68
Price
€90.06
GF Value